技术与方法 |
|
|
|
|
抗EGFRvIII噬菌体抗体库的构建和筛选 |
周敏,石必枝,顾健人,李宗海** |
上海交通大学医学院上海市肿瘤研究所癌基因及相关基因国家重点实验室 上海 200032 |
|
Construction and Screening of Phage Antibody Libraries Against Epidermal Growth Factor Receptor Variant Type III |
ZHOU Min,SHI Bi-zhi,GU Jian-ren,LI Zong-hai |
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Medical School of Shanghai Jiaotong University, Shanghai 200032, China |
[1] Kuan C T, Wikstrand, C J, Bigner, D D.EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer, 2001, 8(2): 8396.
[2] Pedersen M W, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy. Ann Oncol, 2001, 12(6): 745760.
[3] Fukai J, Nishio K, Itakura T, et al. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci, 2008, 99(10): 20622069.
[4] Wikstrand C J, Hale L P, Batra S K, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res, 1995, 55(14): 31403148.
[5] Li D, Ji H, Zaghlul S, et al. Therapeutic antiEGFR antibody 806 generates responses in murine de novo EGFR mutantdependent lung carcinomas. J Clin Invest, 2007, 117(2): 346352.
[6] Azzazy H M, Highsmith W E. Phage display technology: clinical applications and recent innovations. Clin Biochem, 2002, 35(6): 425445.
[7] 王华茂. 抗EGFRvIII单克隆抗体制备及其在肝癌治疗中的应用. 上海:复旦大学医学院,2009. Wang H M. Epidermal Growth Factor Receptor vIII antibody development and application in hepatocellular carcinoma therapy. Shanghai:Shanghai Medical College of Fudan University,2009.
[8] 江秀玲,毕富勇,王华茂,等. 稳定表达EGFRvIIIex的NIH3T3细胞株的建立及其免疫原性分析. 细胞与分子免疫学杂志,2007,23(7):612615. Jiang X L, Bi F Y, Wang H M, et al. Chinese Journal of Cellular and Molecular Immunology,2007,23(7):612615.
[9] Shi B Z, Wang H M, Guo S R, et al. Protein IIIbased singlechain antibody phage display using bacterial cells bearing an additional genome of a geneIIIlacking helper phage. BioTechniques, 2007, 42(6): 760765.
[10]Hudson P J, Souriau C. Engineered antibodies. Nat Med, 2003, 9(1): 129134. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|